Hospital Medicine

During the annual ASH meeting, investigators issue new clinical development guidelines for sickle cell disease therapies.

A new analysis has found the switch to the “increased-risk” donor classification by the US Public Health Service has had minimal impact on outcomes of lung transplants.

Patients want to engage with their physicians in ways that are easy and convenient for them, according to a recent 1000-patient survey.

In a new trial, investigators find glecaprevir and pibrentasvir is safe to treatment HCV patients who failed treatment with an NS5A inhibitor.

An analysis from the University of Michigan has found postoperative myocardial infarction is still associated with an increased risk of mortality, despite use of evidence-based strategies.

In a new study, investigators find that good dietary habits do not necessarily reduce the risk of dementia later in life.

A new analysis is painting a clearer picture of the impact and causes of the rise and fall of US life expectancy between 1959 and 2017.

A new cohort analysis shows hospitalized smokers are not at complication risk due to the perioperative therapy.

As I prepare for my Thanksgiving meal, I’m struck by the number of CPT codes that physicians may have to use this season.

Results of the ESETT trial are revealing there is little difference in the effectiveness or safety profiles of three anti-seizure treatments for patients with a severe form epilepsy.

Evaluating the impact of DAPA-HF and other recent data that have changed the way cardiologists view the potential uses of SGLT2 inhibitors in patients with or without diabetes.

Novartis AG is set to acquire The Medicines Company in a $9.7 billion deal that is set to be completed in the first quarter of 2020.

How cardiologists have forged the often different goals of improving patients' life expectancies, with improving their quality of life.

The adult heart failure study is the first of its kind: a completely decentralized, indication-seeking clinical trial.

During Kidney Week, Katherine Tuttle, MD, discusses the plethora of options available to nephrologists, including dulaglutide.

Matthew Weir, MD, discusses the START-CKD trial at Kidney Week.

The rate of ED cases have decreased over years, yet proper patient follow-up is still lacking.

Brad Rovin, MD, of The Ohio State University, discusses during Kidney Week what is needed for better outcomes for patients with lupus nephritis.

A new 7-year analysis from the University of Cambridge is shining light on the underlying causes of the "weekend effect" in emergency departments.

Despite a higher genetic risk, investigators link physical activity with decreased odds for developing depression.

David Ludvigson and Nam Tran, PhD, write about the need for rapid triage testing as a method of improving outcomes for patients with acute kidney injury.

Hahn will replace Ned Sharpless, MD, who took over after former commissioner Scott Gottlieb stepped away from the role earlier this year.

A new Mayo Clinic study has found that patients with microvascular endothelial dysfunction were more than twice as likely to be diagnosed with solid-tumor cancer than their counterparts without dysfunction.

The supplemental new drug application was approved based on results of a phase 3 trial in which IV-to-oral delafloxacin met the primary end point of statistical non-inferiority to moxifloxacin.

Dawn Rotellini, chief operating officer of the National Hemophilia Foundation, discusses the important of including patient advocacy groups in annual meetings such as the NORD Summit.